Citigroup
LFCR icon

Citigroup’s Lifecore Biomedical LFCR Stock Holding History

Citigroup’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.17K Buy
2,464
+774
+46% +$5.34K ﹤0.01% 5074
2025
Q4 		$13.8K Buy
1,690
+703
+71% +$5.2K ﹤0.01% 4964
2025
Q3 		$7.26K Sell
987
-9,581
-91% -$72.5K ﹤0.01% 5111
2025
Q2 		$85.8K Sell
10,568
-7,768
-42% -$52.4K ﹤0.01% 4485
2025
Q1 		$129K Buy
18,336
+60
+0.3% +$373 ﹤0.01% 4448
2024
Q4 		$136K Buy
18,276
+962
+6% +$6.14K ﹤0.01% 4675
2024
Q3 		$85.4K Buy
17,314
+11,571
+201% +$60.4K ﹤0.01% 4838
2024
Q2 		$29.5K Sell
5,743
-122,809
-96% -$727K ﹤0.01% 4876
2024
Q1 		$683K Buy
128,552
+31,202
+32% +$223K ﹤0.01% 3330
2023
Q4 		$603K Buy
97,350
+63,732
+190% +$442K ﹤0.01% 3262
2023
Q3 		$254K Buy
33,618
+32,224
+2,312% +$295K ﹤0.01% 3536
2023
Q2 		$13.5K Buy
1,394
+110
+9% +$672 ﹤0.01% 5027
2023
Q1 		$4.85K Buy
1,284
+1,107
+625% +$6.17K ﹤0.01% 4952
2022
Q4 		$1.15K Sell
177
-220
-55% -$1.81K ﹤0.01% 5374
2022
Q3 		$4K Sell
397
-1,509
-79% -$15.3K ﹤0.01% 5309
2022
Q2 		$19K Buy
1,906
+780
+69% +$7.72K ﹤0.01% 5034
2022
Q1 		$13K Sell
1,126
-5,744
-84% -$64K ﹤0.01% 5395
2021
Q4 		$76K Buy
6,870
+2,834
+70% +$27.5K ﹤0.01% 4872
2021
Q3 		$37K Buy
4,036
+2,252
+126% +$24.5K ﹤0.01% 4900
2021
Q2 		$20K Sell
1,784
-205
-10% -$2.36K ﹤0.01% 5301
2021
Q1 		$21K Sell
1,989
-5,729
-74% -$64.4K ﹤0.01% 5223
2020
Q4 		$84K Buy
7,718
+4,526
+142% +$46.8K ﹤0.01% 5668
2020
Q3 		$31K Sell
3,192
-4,788
-60% -$45.6K ﹤0.01% 5902
2020
Q2 		$64K Buy
7,980
+138
+2% +$1.42K ﹤0.01% 5878
2020
Q1 		$68K Buy
7,842
+2,563
+49% +$26.7K ﹤0.01% 5684
2019
Q4 		$60K Sell
5,279
-4,061
-43% -$43.2K ﹤0.01% 6164
2019
Q3 		$102K Sell
9,340
-335
-3% -$3.65K ﹤0.01% 5654
2019
Q2 		$91K Buy
9,675
+948
+11% +$9.57K ﹤0.01% 5959
2019
Q1 		$107K Buy
8,727
+1
+0% +$12 ﹤0.01% 5681
2018
Q4 		$103K Buy
8,726
+1,246
+17% +$17.1K ﹤0.01% 5625
2018
Q3 		$108K Buy
7,480
+2,051
+38% +$28.4K ﹤0.01% 5824
2018
Q2 		$81K Buy
5,429
+1,258
+30% +$17.5K ﹤0.01% 5899
2018
Q1 		$55K Buy
4,171
+377
+10% +$4.95K ﹤0.01% 6091
2017
Q4 		$48K Sell
3,794
-4,464
-54% -$56.4K ﹤0.01% 6215
2017
Q3 		$108K Sell
8,258
-1,582
-16% -$20.9K ﹤0.01% 5507
2017
Q2 		$146K Buy
9,840
+8,171
+490% +$114K ﹤0.01% 5043
2017
Q1 		$20K Sell
1,669
-26,267
-94% -$333K ﹤0.01% 6255
2016
Q4 		$386K Buy
27,936
+24,749
+777% +$343K ﹤0.01% 4652
2016
Q3 		$43K Sell
3,187
-1,000
-24% -$12.1K ﹤0.01% 5760
2016
Q2 		$45K Sell
4,187
-43,075
-91% -$475K ﹤0.01% 5629
2016
Q1 		$496K Buy
47,262
+38,623
+447% +$424K ﹤0.01% 4119
2015
Q4 		$102K Buy
8,639
+8,340
+2,789% +$102K ﹤0.01% 5356
2015
Q3 		$4K Sell
299
-267
-47% -$3.54K ﹤0.01% 6819
2015
Q2 		$8K Sell
566
-1,211
-68% -$17.5K ﹤0.01% 6565
2015
Q1 		$25K Sell
1,777
-3,174
-64% -$43.9K ﹤0.01% 5968
2014
Q4 		$69K Buy
4,951
+2,944
+147% +$38K ﹤0.01% 5481
2014
Q3 		$25K Sell
2,007
-1,090
-35% -$13.6K ﹤0.01% 5759
2014
Q2 		$39K Sell
3,097
-3,487
-53% -$41K ﹤0.01% 5330
2014
Q1 		$74K Sell
6,584
-7,109
-52% -$78K ﹤0.01% 5228
2013
Q4 		$166K Buy
13,693
+13,582
+12,236% +$162K ﹤0.01% 4820
2013
Q3 		$1K Sell
111
-256
-70% -$3.57K ﹤0.01% 6677
2013
Q2 		$4K Buy
+367
New +$5.08K ﹤0.01% 6384

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's LFCR Position: Q1 2026 in Review

Citigroup increased its Lifecore Biomedical (LFCR) stake by 46% in Q1 2026, buying an estimated $5.34K and bringing the position to 2,464 shares worth $9.17K. The position accounts for ﹤0.01% of the portfolio, ranked #5074.

Citigroup first reported a position in LFCR in Q2 2013 and has held it in 52 quarters since. The position peaked at $683K in Q1 2024. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Citigroup held 2,464 shares of Lifecore Biomedical worth $9.17K as of Q1 2026.
  • Citigroup bought 774 Lifecore Biomedical shares in Q1 2026, an estimated $5.34K.
  • Lifecore Biomedical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5074 holding.
  • Citigroup first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Lifecore Biomedical position peaked at $683K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.